Reply  by Wharton, Thomas P et al.
REPLY
We appreciate the kind comments and provocative suggestions of
Kereiakes et al. We particularly relish the appellation “bell
weather” (sic). (While “Bellwether” connotes leadership, we hope
the writers did not intend the term’s more literal Old English
usage: a gelded male sheep wearing a bell leading a foolish flock!)
(1).
In our manuscript (2), we did not intend to propose detailed
primary angioplasty guidelines nor formal protocols for general use
at nonsurgical hospitals. Such a project would require much input
from numerous sources. We do agree with Kereiakes et al. that
experienced, high-volume operators are essential to the success of
such programs, as are an experienced support team (see paragraph
5 below) and formalized transfer protocols.
We do not believe that reports of less favorable outcomes of
coronary intervention at lower-volume hospitals should be a reason
to limit primary angioplasty to higher-volume hospitals, for mul-
tiple reasons:
1. The reported differences in mortality for elective angioplasty
between the lowest- and highest-volume hospitals are very
small. A recent American College of Cardiology (ACC) clinical
competence statement on coronary intervention (3) included
reviews of 11 papers that related institutional interventional
volume to outcomes. Only 3 of these 11 (4–6) found any
relation between institutional volume and mortality in hospitals
in the early 1990s performing over 25 to 50 cases a year; these
differences in absolute mortality were only 0.2% to 0.8%. Five of
the 11 studies examined data on patients with acute myocardial
infarction (AMI) (7–11); none of these five found any volume-
related mortality differences in hospitals performing over 40 to
50 cases annually.
2. Lower-volume hospitals may perform a disproportionately
larger percentage of interventions on patients with high-risk
diagnoses such as AMI. Most of the above reports do not use
risk-adjusted data, and thus they may have “disregarded robust
risk factors that explain most of the variation in outcome
attributed to hospital volume” (12).
3. All else being equal, AMI patients might have a very slight
advantage if they were to present to a higher-volume rather
than a lower-volume hospital—if each facility practiced primary
angioplasty routinely. But all else is not equal. We must
compare the outcomes of primary angioplasty at lower-volume
hospitals, not to outcomes at higher-volume hospitals, but
rather to the risk of not offering reperfusion therapy at all to the
majority of patients who are lytic-ineligible, or to the risk and
delay of transfer of such patients to a willing surgical center for
primary angioplasty. The differences in mortality among these
alternatives may be far greater than the #0.8% cited above. As
yet, there is no “evidence-based” reason to conclude that either
of these two alternatives is superior to early primary angioplasty
on-site. Unfortunately, randomized studies of such issues have
met with only limited success in enrolling patients.
4. Outcomes data on low-volume hospitals may disproportion-
ately reflect the outcomes of low-volume operators. Outcomes
of high-volume operators at low-volume institutions have not
been examined. We propose that primary angioplasty be per-
formed at such hospitals only by higher-volume operators who
also routinely perform elective angioplasty at surgical centers.
5. We agree that primary angioplasty is different from elective
angioplasty and that it requires simultaneous intensive medical
care of the acutely ill AMI patient. Relatively more patients
with AMI present to community hospitals than to tertiary
centers. Thus, the nursing and technical staff at smaller hospi-
tals may already have thorough experience in the medical care
of such patients. Further, smaller hospitals with only one
catheterization team and few operators may gain more experi-
ence in performing primary angioplasty—on a per operator and
per team basis—than larger surgical centers with many more
teams and operators. (Many high-volume hospitals and opera-
tors perform little if any primary angioplasty, having full
schedules that do not easily permit interruptions).
6. Available evidence from many reported series besides our own
indicates that qualified hospitals without cardiac surgery can
achieve primary angioplasty that are similar to those of high-
volume surgical centers (13–23).
7. In the ACC clinical competence statement (3), Hirshfield et al.
note that the studies cited therein were before the era of stents
and platelet GP IIb/IIIa inhibitors, and they observe, “It is
likely that the availability of these treatments has reduced the
expected frequency of death and emergency CABG. . . . Con-
sequently, these data may not accurately reflect current prac-
tice.” Along these same lines, Teirstein (24) editorializes that
“the dramatically low event rate [with stents and newer anti-
platelet regimens] begs the question: Is elective coronary
stenting now so predictable that outcomes are not longer
operator dependent?” Teirstein goes on to add, “Recent data
support the use of a direct mechanical approach to acute
infection. However, widespread acceptance of this technique
will require increased patient access to adequate physician and
institutional expertise. . . . Therefore, to achieve overall public
health benefits, credentialing for these urgent procedures may
necessarily be different from elective procedures” [italics added].
We agree with Kereiakes et al. that launching a primary angio-
plasty program may be a daunting challenge, both logistically and
economically, at small hospitals. This challenge has been success-
fully met by over 50 hospitals without cardiac surgery in the U.S.
(15–22; personal survey by Wharton) and by large numbers of
hospitals around the globe (11,13,14,23). Regarding the “cost
consequences,” primary angioplasty may be more cost-effective
than fibrinolytic therapy (25–28). The addition of stents and
platelet GP IIb/IIIa inhibitors, while greatly enhancing the safety
of primary angioplasty, may also further enhance its cost-
effectiveness (29–33).
We disagree that newer pharmacology is likely to render primary
angioplasty “obsolete.” Two-thirds of patients with AMI are not
candidates for fibrinolytic therapy, either because they have bleed-
ing risks, shock, present late, or do not have diagnostic electrocar-
diograms; these patients are generally at higher risk than
fibrinolytic-eligible patients, and they need a reperfusion alterna-
tive to “morphine and bedrest” (34–37). Further, the citation by
Kereiakes et al. of a 70% reperfusion rate at 60 min for patients
treated with combination fibrinolytic and platelet GP IIb/IIIa
inhibitor therapy is based on very small numbers of patients in two
pilot studies (38,39) and thus is not yet thoroughly “evidence-
based.”
Kereiakes and colleagues cite the time delay for primary angio-
plasty as a disadvantage. Time delay, of course, is a factor in both
higher- and lower-volume hospitals. Regardless, the outcomes of
primary angioplasty are better than those of fibrinolytic therapy
(40) and are not nearly so time-dependent (41). In fact, if the
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average “door-to-needle” time is as long as 45 min (10) and the
average “needle-to-reperfusion” time is 60 to 90 min (42), then the
average time-to-reperfusion for the small majority of fibrinolytic-
treated patients who do achieve TIMI flow grade 3 (43) is very
similar to the time-delay for on-site primary angioplasty. The
latter treatment results in reperfusion in about 95% of patients
(44–50) and can be applied to a much greater proportion of
patients with AMI at capable centers.
Offering effective primary angioplasty at the point of first
contact can provide the most rapid reperfusion alternative for the
two-thirds of patients with AMI who are not lytic-eligible. This
may be particularly important for patients in cardiogenic shock. In
the SHOCK study (51), revascularization in under 6 h after onset
of AMI conferred the greatest survival advantage of all descriptors
examined. However, universal triage of AMI patients to high-
volume hospitals could quickly flood the capability of their cath-
eterization laboratories, which often are already working at full
capacity. One possible solution is the establishment of specialized
“Emergency Heart Attack Treatment Centers” with around-the-
clock primary angioplasty capability (though not necessarily with
on-site cardiac surgery) to which all patients with AMI could be
triaged by ambulance.
We agree that updated guidelines are now needed that will more
fully address the performance of primary angioplasty at nonsurgical
hospitals. Input from physicians who practice in these circum-
stances should be sought. It is now not only possible, but in fact
imperative, to offer this potentially life-saving therapy to more
patients with AMI in broader geographical locations.
Thomas P. Wharton Jr., MD, FACC
Nancy Sinclair McNamara, RN, BSN
Frank A. Fedele, MD, FACC
Mark I. Jacobs, MD, FACC
Alan R. Gladstone, MD
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Nonocclusive Coronary
Dissections: To Stent or Not to Stent?
Cappelletti et al. (1) reviewed the outcome of 129 consecutive
patients treated with conventional angioplasty (PTCA) at a time
when coronary stents were not available. Patients (45; 35%)
presenting nonocclusive dissections post-PTCA had a significantly
lower restenosis rate than patients without dissections (12% vs.
44%; p , 0.001). The restenosis rate in another group of patients
undergoing stenting for nonocclusive dissection (clinically and
angiographically matched), later on in their experience, was 25%
(1). At a time when coronary stenting is experiencing an exponen-
tial increase, these results would appear rather provocative. Some
classical studies, however, also suggested that most dissections are
not only benign but also predict a lower restenosis rate (2,3).
Nevertheless, no previous study was able to demonstrate such a low
restenosis rate in this cohort of patients.
Furthermore, to demonstrate convincingly that a conservative
approach—namely a “watchful waiting” strategy—may even be
superior in the long run to coronary stenting is much more
challenging. Given the potential clinical implications of this study,
some methodological clarifications appear warranted.
First, it is not clear why two patients with vessel closure were
excluded. Keeping in mind that this is a retrospective study, it will
be important to know whether these dissections were flow-limiting
immediately after PTCA or flow deterioration occurred later on.
Second, 67% (33/49) of the nontreated dissections were type A
versus none (0/60) of the stented dissections (chi-square p ,
0.0001). Therefore, it is difficult to assume that these two popu-
lations were similar, and thus direct comparison of results may not
be appropriate. Further details on whether the restenosis rate
tended to cluster around patients with type C-D dissections
(untreated/stented groups) will be helpful.
Finally, the methodology of quantitative coronary analysis was
not specified. This is relevant because the analysis of dissected
coronary segments is technically demanding. In fact, at first glance
it appears difficult to explain a mean lumen diameter post-PTCA
of 3.23 6 0.65 mm (reference 3.20 6 0.54 mm) yielding a 20 6
7% diameter stenosis. The large lumen diameter of the dissected
segments indicates that the dissection image was fully included
into the lumen measurements. This is in contradistinction with
some prior studies using careful edge-detection quantitative an-
giography (4,5). We previously demonstrated (5) that residual
coronary dissections after stenting had a benign outcome when
they were stable, were not associated with significant lumen
narrowing, and did not compromise coronary flow.
Our data (5) also concur with the current study, suggesting that
most residual dissections disappear at follow-up. Moreover, these
dissected coronary segments may promote a unique pattern of
vessel remodeling that could explain a lower restenosis rate (1) or
even a significant lumen improvement on late angiography (5). We
fully agree with the idea that conservative management of coronary
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